Leishmania-HIV interaction: immunopathogenic mechanisms.
about
In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensisContribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionHIV infection and tropical parasitic diseases - deleterious interactions in both directions?Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replicationDrought, smallpox, and emergence of Leishmania braziliensis in northeastern Brazil.Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1.Importance of nonenteric protozoan infections in immunocompromised people.A case for a neonatal, low-dose BCG vaccination trial.Parasitic diseases and immunodeficiencies.Treatment of visceral leishmaniasis: a review of current treatment practices.High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assayTh1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergyHIV and helminth co-infection: is deworming necessary?Inhibition of growth of Leishmania donovani promastigotes by newly synthesized 1,3,4-thiadiazole analogs.Tracing immunity to human leishmaniasis.Decreased memory T-cell response and function in human immunodeficiency virus-infected patients with tegumentary leishmaniasis.Immunological perspectives of leishmaniasis.Human immunodeficiency virus/acquired immunodeficiency syndrome and tropical diseases: a Brazilian perspective.Antileishmanial activity of an indole alkaloid from Peschiera australis.Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.Membranoproliferative glomerulonephritis due to visceral leishmaniasis in an HIV patient.Paromomycin: uptake and resistance in Leishmania donovani.Facilitation through altered resource availability in a mixed-species rodent malaria infection.Activity of hydroxyurea against Leishmania mexicana.A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus.Increased expression of HIV co-receptor CXCR4 on CD4+ T-cells in patients with active visceral leishmaniasis.Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan.Partners in crime: co-infections in the developing worldOral leishmaniasis: a clinicopathological study of 11 cases
P2860
Q24536041-84F6B961-A5E2-4BA7-97B4-7AE631B22D7CQ24550678-69F6AB3A-3882-4DD9-8D1A-ACD0DE576A75Q28198124-BFD20426-F1A8-4CD4-9DC3-2FD1EB8C785EQ28343594-4492CCCE-55F8-4FB3-8DA9-354A1CD5FA22Q30438890-96666A79-B13F-424D-BC97-035D524D1E4CQ33949743-D95747D4-420E-4AD0-8F62-9ED35A4F9369Q33971021-BDEC0978-4DCE-435D-A752-6088D064EC97Q34189873-457E4926-7B3C-4B4C-BE0A-8AC4A65F842CQ34246782-32F0FD4D-791E-4EED-BCF3-47479EB19DECQ34301450-A2B0445B-6986-438A-9B9F-26E3AD5BDABEQ34768497-8D0617AC-824A-407E-95DA-34A590384D0CQ35079712-054DA979-53E6-4E7C-B49D-56EAA120C9A9Q35271085-F70D4C9E-E5CA-470F-BF5C-A4D7CA51D175Q35920663-36B148D9-1447-4D3A-A6F9-3D7B96C7200FQ36624193-24B962D1-CAE3-46F0-BE37-8E7345FD043BQ37063382-A7D534D1-FB68-4DF5-A387-ED299CFEE831Q37405618-4E938459-2356-4E02-BC13-51222F3F8118Q37684684-5AF4B657-8C8B-4D4F-A806-BCD17E16F2E3Q37770420-F2F68B21-3EE2-4020-8A31-836B5978040CQ39268457-7F858469-4409-4880-BA8E-CA4E84DE4186Q39477065-C745EB48-4D59-4596-AC34-2DF6C261392AQ39526125-AC8F13C0-562C-41DD-A7C4-107C7D0EE85EQ40805084-22485A9C-CFA8-49F7-8949-0E8E050132F1Q41552929-613C04F1-DF95-4632-94C1-F6F6A288C0C4Q41855565-BBDE4840-F952-4657-9BB0-FD86759659CAQ42394489-5F9E9B30-37D4-41AC-A6E7-D1C2C1516E25Q43189699-45A73C40-C122-44CE-8D31-F31F6898F613Q45732220-FDA981D8-FDA1-493D-8A83-B4D3E1973796Q46187009-45F37FAD-3D41-4379-AD7D-A57563EC4BCEQ47225733-51BFE983-8388-4700-8CEE-AC5EC3B8FDF4Q56920473-C6689364-A3B8-4DA3-82B0-6D1D0AB99C3FQ57980019-9BF3851C-F694-4662-8557-7191D1F3272E
P2860
Leishmania-HIV interaction: immunopathogenic mechanisms.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Leishmania-HIV interaction: immunopathogenic mechanisms.
@ast
Leishmania-HIV interaction: immunopathogenic mechanisms.
@en
type
label
Leishmania-HIV interaction: immunopathogenic mechanisms.
@ast
Leishmania-HIV interaction: immunopathogenic mechanisms.
@en
prefLabel
Leishmania-HIV interaction: immunopathogenic mechanisms.
@ast
Leishmania-HIV interaction: immunopathogenic mechanisms.
@en
P2093
P1476
Leishmania-HIV interaction: immunopathogenic mechanisms.
@en
P2093
P304
P356
10.1016/S0169-4758(99)01431-3
P577
1999-05-01T00:00:00Z